Logo do repositório
 
Publicação

A genetically modified Plasmodium berghei parasite as a surrogate for whole-sporozoite vaccination against P. vivax malaria

2022Artigo científico Acesso aberto
Ver registo simples
dc.contributor.authorMoita, Diana
dc.contributor.authorMaia, Teresa G.
dc.contributor.authorDuarte, Miguel
dc.contributor.authorAndrade, Carolina M.
dc.contributor.authorAlbuquerque, Inês S.
dc.contributor.authorDwivedi, Ankit
dc.contributor.authorSilva, Joana C.
dc.contributor.authorGonzález-Céron, Lilia
dc.contributor.authorJanse, Chris J.
dc.contributor.authorMendes, António M.
dc.contributor.authorPrudêncio, Miguel
dc.date.accessioned2023-02-03T15:42:03Z
dc.date.available2023-02-03T15:42:03Z
dc.date.issued2022
dc.description© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.pt_PT
dc.description.abstractTwo malaria parasite species, Plasmodium falciparum (Pf) and P. vivax (Pv) are responsible for most of the disease burden caused by malaria. Vaccine development against this disease has focused mainly on Pf. Whole-sporozoite (WSp) vaccination, targeting pre-erythrocytic (PE) parasite stages, is a promising strategy for immunization against malaria and several PfWSp-based vaccine candidates are currently undergoing clinical evaluation. In contrast, no WSp candidates have been developed for Pv, mainly due to constraints in the production of Pv sporozoites in the laboratory. Recently, we developed a novel approach for WSp vaccination against Pf based on the use of transgenic rodent P. berghei (Pb) sporozoites expressing immunogens of this human-infective parasite. We showed that this platform can be used to deliver PE Pf antigens, eliciting both targeted humoral responses and cross-species cellular immune responses against Pf. Here we explored this WSp platform for the delivery of Pv antigens. As the Pv circumsporozoite protein (CSP) is a leading vaccine candidate antigen, we generated a transgenic Pb parasite, PbviVac, that, in addition to its endogenous PbCSP, expresses PvCSP under the control of a strictly PE promoter. Immunofluorescence microscopy analyses confirmed that both the PbCSP and the PvCSP antigens are expressed in PbviVac sporozoites and liver stages and that PbviVac sporozoite infectivity of hepatic cells is similar to that of its wild-type Pb counterpart. Immunization of mice with PbviVac sporozoites elicits the production of anti-PvCSP antibodies that efficiently recognize and bind to Pv sporozoites. Our results warrant further development and evaluation of PbviVac as a surrogate for WSp vaccination against Pv malaria.pt_PT
dc.description.sponsorshipA.D. and J.C.S. were supported by the National Institute of Allergy and Infectious Diseases, National Institutes of Health (U19AI110820 and R01AI141900). A.M.M. acknowledges Fundação para a Ciência e Tecnologia, Portugal (FCT) for Grant PTDC-BBB-BMD-2695-2014. M.P. acknowledges the “la Caixa” Foundation for Grant HR21-848, the GSK OpenLab Foundation for grant TC269, and FCT for grant PTDC-SAU-INF-29550-2017. D.M. acknowledges FCT for grant SFRH/BD/144817/2019.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationNPJ Vaccines. 2022 Dec 16;7(1):163pt_PT
dc.identifier.doi10.1038/s41541-022-00585-8pt_PT
dc.identifier.eissn2059-0105
dc.identifier.urihttp://hdl.handle.net/10451/56144
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherSpringer Naturept_PT
dc.relationPTDC-BBB-BMD-2695-2014pt_PT
dc.relationPTDC-SAU-INF-29550-2017pt_PT
dc.relationExploiting innate immune responses to enhance antimalarial vaccination
dc.relation.publisherversionhttps://www.nature.com/npjvaccines/pt_PT
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/pt_PT
dc.titleA genetically modified Plasmodium berghei parasite as a surrogate for whole-sporozoite vaccination against P. vivax malariapt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.awardNumberSFRH/BD/144817/2019
oaire.awardTitleExploiting innate immune responses to enhance antimalarial vaccination
oaire.awardURIinfo:eu-repo/grantAgreement/FCT//SFRH%2FBD%2F144817%2F2019/PT
oaire.citation.issue1pt_PT
oaire.citation.titlenpj Vaccinespt_PT
oaire.citation.volume7pt_PT
person.familyNameAlves Moita
person.familyNameGonçalves Carreira Maia
person.familyNameAndrade
person.familyNameS. Albuquerque
person.familyNameM. Mendes
person.familyNamePrudêncio
person.givenNameDiana
person.givenNameTeresa
person.givenNameCarolina
person.givenNameInês
person.givenNameAntónio
person.givenNameMiguel
person.identifier361994
person.identifierhttps://scholar.google.pt/citations?user=zduN6wsAAAAJ&hl=pt-PT&oi=ao
person.identifier.ciencia-idFC1B-A174-8DFD
person.identifier.ciencia-id2319-7D78-2F85
person.identifier.ciencia-idAA13-20AA-F50C
person.identifier.ciencia-id4E15-FAB8-D7D1
person.identifier.ciencia-id5511-16ED-48E0
person.identifier.orcid0000-0002-7958-8630
person.identifier.orcid0000-0002-2814-6402
person.identifier.orcid0000-0002-9763-8857
person.identifier.orcid0000-0002-1108-0961
person.identifier.orcid0000-0001-6562-5325
person.identifier.orcid0000-0003-1746-6029
person.identifier.ridP-5325-2016
person.identifier.scopus-author-id14028767900
person.identifier.scopus-author-id6603561872
project.funder.identifierhttp://doi.org/10.13039/501100001871
project.funder.nameFundação para a Ciência e a Tecnologia
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublication49563c3a-d313-4cfb-93ee-afe720ca5dc5
relation.isAuthorOfPublication90cf3ff0-113d-424d-82a4-d497ea263a57
relation.isAuthorOfPublicationd8091bd1-43e3-4972-8bd8-be3499e4a30b
relation.isAuthorOfPublication37a8c939-e874-41d7-86bd-9d6d349467e4
relation.isAuthorOfPublicationfb4d97a3-5668-4f60-a5af-7bb8f1175c38
relation.isAuthorOfPublication80e4e74d-bf34-4a71-8530-cc3280543b65
relation.isAuthorOfPublication.latestForDiscovery49563c3a-d313-4cfb-93ee-afe720ca5dc5
relation.isProjectOfPublication655a6cd4-9274-40ac-89c3-7263f2b18567
relation.isProjectOfPublication.latestForDiscovery655a6cd4-9274-40ac-89c3-7263f2b18567

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
Modified_Plasmodium.pdf
Tamanho:
1.28 MB
Formato:
Adobe Portable Document Format
Ver/Abrir
Licença
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
license.txt
Tamanho:
1.2 KB
Formato:
Item-specific license agreed upon to submission
Descrição:
Ver/Abrir

Coleções

IMM - Artigos em Revistas Internacionais
FM - Artigos em Revistas Internacionais